What is ERBB3 gene?

What is ERBB3 gene?

ERBB3 (Erb-B2 Receptor Tyrosine Kinase 3) is a Protein Coding gene. Diseases associated with ERBB3 include Lethal Congenital Contracture Syndrome 2 and Visceral Neuropathy, Familial, 1, Autosomal Recessive.

What is ErbB2 gene?

The erbB2 (also known as HER2 or neu) gene encodes a 185-kDa transmembrane glycoprotein, which belongs to the epidermal growth factor receptor (EGFR) family. ErbB2 is a receptor tyrosine kinase with intrinsic tyrosine kinase activity.

What is HER3 breast cancer?

HER3 is emerging as a crucial biomarker in luminal breast cancers. HER3 mRNA is expressed significantly in estrogen receptor positive (ER+) or luminal tumors, consistent with the observation that HER3 is essential for cell survival in the luminal but not the basal normal mammary epithelium.

What is the difference between HER2 and HER3?

In addition to abnormal overexpression, HER2 is also able to spontaneously homodimerize [16]. In contrast to HER2, HER3 can bind multiple ligands (neuregulins) [20] but it lacks a functioning kinase domain [21] and is, therefore, unable to homodimerize and to induce downstream signaling pathway activation on its own.

Where is EGFR located?

Epidermal growth factor receptor

Is HER2 and ERBB2 the same?

The HER2 is the legacy gene symbol for ERBB2 and may be more commonly used by the community; HER2 is also commonly used to describe the protein encoded by the ERBB2 gene. One unique feature of HER2 compared with the other receptors in the HER family is the absence of a known ligand.

What is the function of ERBB2?

Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane.

Is HER3 a GFR?

The human epidermal growth factor receptor (EGFR) family consists of four tyrosine kinase receptors (EGFR/HER1, HER2, HER3, and HER4) that stimulate growth signaling pathways involved in cell proliferation, growth, survival, and differentiation.

What is HER3 gene?

Receptor tyrosine-protein kinase erbB-3, also known as HER3 (human epidermal growth factor receptor 3), is a membrane bound protein that in humans is encoded by the ERBB3 gene. ErbB3 is a member of the epidermal growth factor receptor (EGFR/ERBB) family of receptor tyrosine kinases.

What happens if EGFR is mutated?

EGFR (epidermal growth factor receptor) is a protein on cells that helps them grow. A mutation in the gene for EGFR can make it grow too much, which can cause cancer.

What is an EGFR inhibitor?

A substance that blocks the activity of a protein called epidermal growth factor receptor (EGFR). EGFR is found on the surface of some normal cells and is involved in cell growth. It may also be found at high levels on some types of cancer cells, which causes these cells to grow and divide.

What is her+?

HER2-positive breast cancer is a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). This protein promotes the growth of cancer cells.

How is ErbB3 mutation used in clinical trials?

ERBB3 Mutation serves as an inclusion eligibility criterion in 8 clinical trials, of which 6 are open and 2 are closed. Of the trials that contain ERBB3 Mutation as an inclusion criterion, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 4 are phase 2 (3 open).

What is the prevalence of ErbB3 kinase domain mutations in lung cancer?

Jeong EG, Soung YH, Lee JW, Lee SH, Nam SW, Lee JY, et al. ERBB3 kinase domain mutations are rare in lung, breast and colon carcinomas. Int J Cancer. 2006;119:2986–7.

What is the prevalence of nonsense or frameshift ErbB3 mutations?

Nonsense or frameshift ERBB3 mutations are rare in cancer, as they are for most oncogenes. We searched COSMIC [ 34] in May 2019 for all ERBB3 mutations (Supplementary Table 1 ): of 1210 reported mutations, 62 (5.1%) are nonsense or frameshift mutations.

What is the prevalence of erbb3-mutant tumors?

Thirty-one patients with an ERBB3 -mutant tumor were reported, representing 3.8% of 844 patients with various tumor types that were screened for molecular alterations. Twelve mutations were located at known hotspots, including V104 and E928.